The estimated Net Worth of William J Motto is at least 3.16 百万$ dollars as of 5 March 2013. William Motto owns over 2,500 units of Meridian Bioscience stock worth over 2,563,308$ and over the last 21 years William sold VIVO stock worth over 598,413$.
William has made over 10 trades of the Meridian Bioscience stock since 2011, according to the Form 4 filled with the SEC. Most recently William sold 2,500 units of VIVO stock worth 53,975$ on 5 March 2013.
The largest trade William's ever made was exercising 44,896 units of Meridian Bioscience stock on 12 September 2011 worth over 93,833$. On average, William trades about 1,560 units every 7 days since 2003. As of 5 March 2013 William still owns at least 75,458 units of Meridian Bioscience stock.
You can see the complete history of William Motto stock trades at the bottom of the page.
William's mailing address filed with the SEC is MERIDIAN DIAGNOSTICS INC, 3471 RIVER HILLS DRIVE, CINCINNATI, OH, 45244.
Over the last 22 years, insiders at Meridian Bioscience have traded over 8,089,514$ worth of Meridian Bioscience stock and bought 228,244 units worth 3,053,655$ . The most active insiders traders include Richard Eberly、John P. Kenny、John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of 424,761$. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth 173,230$.
Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian Bioscience executives and other stock owners filed with the SEC include: